Wei et al. reported that the limited effect of AZD8055 as an ATP-competitive inhibitor of mTOR in pancreatic cancer cells was partly due to FOXO transcription factor–mediated upregulation of EGFR and its reactivation of Akt activity. This evidence concerns the gene AKT1 and pancreatic neoplasm.